Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 01, 2024 14:00 ET | Source: NMD Pharma

NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences

NMD Pharma announces poster and oral presentations on skeletal muscle targeted ClC-1 therapy at two leading neuromuscular disease conferences ClC-1 is a chloride ion channel specifically expressed...
May 22, 2023 10:05 ET | Source: Baylor Genetics

Baylor Genetics Announces Neuromuscular Disorders Panel

HOUSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory at the forefront of genetic testing and precision medicine, today announced the availability of a...
April 06, 2023 14:30 ET | Source: Transparency Market Research

Cough Assist Devices Market Revenue to Cross USD 480 Mn by 2031 | TMR Study

Wilmington, Delaware, United States, April 07, 2023 (GLOBE NEWSWIRE) -- The global cough assist devices market size was worth USD 218.5 Mn in 2021 and is expected to exceed value of USD 480.7 Mn by...
January 09, 2023 07:00 ET | Source: Lupin Ltd

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders Agreement enables sustainable...
December 14, 2022 07:00 ET | Source: NMD Pharma

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
December 14, 2022 01:00 ET | Source: NMD Pharma

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3

NMD Pharma Receives IND Clearance to Start a Phase II Clinical Trial of NMD670 for the Treatment of Symptoms of Spinal Muscular Atrophy Type 3 Aarhus, Denmark, 14 December 2022 – NMD Pharma A/S, a...
July 08, 2021 07:00 ET | Source: NMD Pharma

NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease

PRESS RELEASE NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease The international observational study will be conducted in collaboration with Aarhus University and...
July 08, 2021 02:00 ET | Source: NMD Pharma

NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease

PRESS RELEASE NMD Pharma Initiates ESTABLISH Study in Patients with Charcot-Marie-Tooth Disease The international observational study will be conducted in collaboration with Aarhus University and...
July 14, 2020 07:00 ET | Source: NMD Pharma

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...
July 14, 2020 02:00 ET | Source: NMD Pharma

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis

NMD Pharma Receives Approval to Start a combined Phase I/IIa Clinical Trial of NMD670 for the Treatment of Symptoms of Myasthenia Gravis Aarhus, Denmark, 14 July 2020 – NMD Pharma A/S, a biotech...